Searchable abstracts of presentations at key conferences in endocrinology

ea0038fut2.1 | Futures 2: Overcoming the consultancy hurdle | SFEBES2015

Kar Partha

Much has been written and discussed about the role of the specialist within the confines of the modern NHS. There is a growing realisation that having a specialist rigidly based in hospital is becoming difficult to sustain; instead, flexibility is now crucial as primary and specialist care look to work together to improve diabetes care.With the challenges of the Five Year Forward View (NHS England, 2014) upon us in England, and similar pressures elsewher...

ea0013p35 | Clinical practice/governance and case reports | SFEBES2007

Pregnancy, hyperaldosteronism and an adrenal mass – were we Conned?

Kar Partha , Cummings Michael

A 30 year old woman presented at 15 weeks gestation with resistant hypertension (that had been diagnosed prior to pregnancy) and hypokalaemia (2.8 mmol/l). Subsequent tests, whilst on Nifedipine, showed a markedly raised aldosterone/renin ratio of 267 (n<25) [Aldosterone 720 ng/L;Renin 3 mu/L] (Aldosterone reference range: Supine:20–190 ng/L, Ambulant 30–340 ng/L; Renin reference range: Supine 2–30 mu/L, Ambulant 3–40 mu/L).<p class="a...

ea0025p199 | Endocrine tumours and neoplasia | SFEBES2011

A case of phaeochromocytoma of the urinary bladder

Bujanova Jana , Mongolu Shiva , Kar Partha

Introduction: Phaeochromocytoma of the urinary bladder is a rare neoplasm and accounts for <1% of all phaeochromocytomas. It is more common in females and the majority of patients present in second and fourth decade. Its common presentation is painless haematuria, headache, palpitation, hypertension and syncope during or immediately after urination.Case history: We present a case of 48-year-old man who presented to Endocrinology with a few months his...

ea0021p331 | Steroids | SFEBES2009

Group education improves patient confidence in managing steroid sick day rules

Munday Linda Jean , Chong Lina , Kar Partha

Background: Group education for patients with diabetes is a well validated method of enhancing self-management skills. More recently some departments have used group education to teach endocrine patients how to administer IM hydrocortisone.Innovation: Patients on steroid replacement, identified by the endocrine nurse and GPs, were invited to attend a group session. The aim was to ensure every relevant patient in the locality had the opportunity to be edu...

ea0065p333 | Neuroendocrinology | SFEBES2019

A rare case of metastatic insulinoma

Millar Kate , Sim Sing Yang , Haider Najaf , Kar Partha

A 24 year old gentleman presented following an episode where he became ‘sleepy’ and disorientated whilst driving and had to pull over. He was confused and lethargic and paramedics found blood glucose of 2 mmol/l. He gave a 3-week history of extreme lethargy, nausea, epigastric discomfort, blurring of vision and constant hunger. He denied recent weight changes and had no significant past medical/family history. Biochemical evaluation was as follows; Laboratory glucose...

ea0065p384 | Reproductive Endocrinology and Biology | SFEBES2019

Its not just the baby that grows in pregnancy

Haider Najaf , Butt Nouman , Millar Kate , Kar Partha

Pituitary apoplexy is a rare but life threatening condition if not diagnosed and treated promptly. Common causes include hypertension, head trauma, major surgery, dynamic pituitary tests, anticoagulant use and pregnancy. In pregnancy, hyperplasia and hypertrophy of the lactotroph cells increase pituitary volume by 45% returning to original size at 6 months post-partum. Pituitary apoplexy is uncommon in pregnancy and an underlying adenoma is usually the cause. Very few...

ea0038p335 | Pituitary | SFEBES2015

Pituitary service review in a District General Hospital: a case for nationally agreed guidelines?

Nicholson Eveleigh , Bujanova Jana , Zarif Nadia , Kar Partha

Background and aims: In 2010 pituitary service improvements were instigated, e.g., creation of local pituitary MDTs/joint pituitary clinics with surgeons. In the absence of national guidelines on post-surgical follow up of pituitary patients there was an evolution of local best practice standards. An audit was conducted in March 2015.Methods: Twenty-six patients underwent pituitary surgery at local tertiary centre in 2013/14 with endocrine care based at ...

ea0015p56 | Clinical practice/governance and case reports | SFEBES2008

Adrenal suppression and intranasal steroid use

Olateju Tolu , Jaleel Nihad , Kar Partha , Atkin Marc , Meeking Darryl

Prolonged use of oral corticosteroid treatment is associated with cushingoid side effects and HPA suppression. We are increasingly seeing similar problems associated with nasal steroid therapy.Case 1: A 41-year-old lady with history of asthma, allergic rhinitis and nasal polyps presented with a clinical appearance of Cushings syndrome. Her medication included Becloforte inhalers 250 mg tds and Betamethasone sodium phosphate nasal drops 0.1% 2 drops bd, b...

ea0065p310 | Neuroendocrinology | SFEBES2019

An audit of Acromegaly patients managed in a large district general hospital

Sim Sing Yang , Munday Jean , Morcombe Amanda , Nicholson Eveleigh , Kar Partha

Acromegaly is a relatively rare disorder with a prevalence of 40 per million. Diagnostic and management process have evolved with time, however lack of statistical facts/data remained an issue.Aims: 1) To look at the cohort of patients who attend our local Endocrine department with a diagnosis of acromegaly. 2) To determine how many are cured with surgery, how many need adjuvant treatment and how many remain uncontrolled despite all treatment modalities....

ea0034p84 | Clinical practice/governance and case reports | SFEBES2014

Long-term follow-up of patients treated with tolvaptan for resistant hyponatraemia

Humayun Malik Asif , Elliot Rosina , Cummings Michael , Kar Partha , Meeking Darryl , Cranston Iain

Background: We previously published data for short-term outcomes in patients with SIADH-related hyponatraemia unresponsive to fluid restriction and treated with tolvaptan. In light of concerns over longer-term side-effects we have revisited the topic and extended both group size and follow-up period to determine longer-term safety and treatment implications.Aims/methods: We report ongoing treatment outcomes (case-note review) for 25 patients (age 71&#177...